A Phase 2 interventional study of GFT505 80mg and GFT505 120mg in Non-Alcoholic Steatohepatitis (NASH), sponsored by Genfit. Completed at 56 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 45th largest by enrollment of the 460 interventional ones that give a count, is one of 11 that started in 2012, is one of 192 in phase 2, and was the 92nd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 275 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver cancer. NAFLD (Non Alcoholic Fatty Liver Disease) is considered as the most common form of chronic liver disease in adults in the United States, Australia, Asia and Europe. In the USA, the estimated prevalence of NAFLD is 20-30% of the adult population.
Non-alcoholic Steatohepatitis (NASH) is a progressing form of NAFLD, which corresponds to hepatic steatosis associated with inflammation and liver cell injury upon microscopic examination of a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and deserves serious medical management. Up to now, there is no effective drug which has clearly demonstrated therapeutic efficacy which may help lifestyle and dietary recommendations in the resolution of NASH.
In this context, GENFIT is developing a new liver targeted drug candidate, GFT505, for the treatment of NASH and the reduction of multiple cardiometabolic risk factors associated with the metabolic syndrome and type 2 Diabetes.
This phase IIb study will evaluate the efficacy and safety of GFT505 80mg and 120mg once daily for 52 weeks on the reversal of NASH without worsening of fibrosis, based on liver biopsy assessments.
The study duration per patient will be 80 weeks. A screening period (from 4 to 16 weeks) will precede a 52-week double-blind treatment period and a 3 months follow-up period.
The study will be conducted in 270 patients (90 patients in the placebo arm, 90 patients in the GFT505 80mg arm, and 90 patients in the GFT505 120mg arm).
Enrollment will be performed in two phases: during the first phase, the patients will receive either GFT505 at a dose of 80 mg either the placebo. An independent expert committee will review the safety data when 45 patients receiving the dose at 80 mg will have been treated for 6 months. The committee approval will be necessary to start the second phase, while the patients will receive either GFT505 at a dose of 80 mg, or GFT505 at a dose of 120 mg or the placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
Drug: GFT505 80mg
Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
Drug: GFT505 120mg
hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
Drug: Placebo
Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)
Percentage of responders from baseline to Week 52 defined by the disappearance of steatohepatitis (ie, participants no longer meeting the criteria for steatohepatitis) without worsening of fibrosis. Worsening of fibrosis was evaluated using Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis staging system and defined as: * Progression to stage 3 or 4 for participants at stage 0, 1 or 2 on diagnostic liver biopsy * Progression to stage 4 for participants at stage 3 on diagnostic liver biopsy
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg the change from baseline to Week 52, in Non-alcoholic Fatty Liver Disease Activity Score (NAS score). NAS score is a composite score equal to the sum of the steatosis grade (0 to 3), lobular inflammation grade (0 to 3) and hepatocellular ballooning grade (0 to 2). The overall scale of the NAS is 0 to 8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points
To evaluate the number of participants with at least a 2 point decrease from baseline in Non-alcoholic Fatty Liver Disease Activity Score (NAS) after 52 weeks of daily administration of GFT505 80mg or 120mg. The NAS refers to the severity of ongoing liver injury as assessed by a liver biopsy and is used to assess the activity of the disease. It is based on the NASH CRN methodology for scoring the severity of steatosis (score of 0 to 3), inflammation (score of 0 to 3), and hepatocellular ballooning (score of 0 to 2), with a maximum score of 8. A total NAS score of five or greater correlates with the diagnosis of steatohepatitis. In table below for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 2 participants (out of 10 participants analysed with a baseline NAS at 3) had at Least 2 points decrease on their NAS after 52 weeks of daily administration of GFT505 80mg. It corresponds to 20% (2 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in steatosis score of at least 1 point between baseline and Week 52. Steatosis is assessed by a liver biopsy and evaluated on a scale of 0 to 3 with higher scores indicating more severe steatosis. A score of 0 indicating a lower severity with low parenchymal involvement (\<5%), while a score of 3 is indicative of higher involvment/severity (\> 66%). In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease Steatosis Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in lobular inflammation score of at least 1 point between baseline and Week 52. Lobular inflammation is assessed by a liver biopsy and evaluated on a scale of 0 to 3. A score of 0 indicating the absence of inflammation loci, while a score of 3 is indicative of a higher degree of inflammation with more than 4 inflammation loci 200 x field. In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Lobular Inflammation Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in ballooning score of at least 1 point between baseline and Week 52. Ballooning is assessed by a liver biopsy and evaluated on a scale of 0 to 2 with higher scores indicating more severe ballooning (0: No ballooned cells, 1: Few \[rare but definite\] ballooned hepatocytes; 2: Many ballooned cells/prominent ballooning). In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 4 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Ballooning Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in the Stages of Fibrosis
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in stages of fibrosis (based on Non-Alcoholic Steatohepatitis Clinical Research Network \[NASH CRN\] scoring). Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in liver enzymes.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in aspartate transaminase/alanine aminotransferase ratio
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK 18-M65 (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK18 M30 (non-invasive markers of fibrosis and steatosis). Participants with missing data for CK18 M30 at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in adiponectin (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in ferritin (non-invasive markers of fibrosis and steatosis). Participants with missing data for Ferritin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in FG19 and FG21 (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in alpha2 macroglobulin (a non-invasive marker of fibrosis and steatosis). Participants with missing data for Alpha2 Macroglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in hyaluronic acid, N-terminal pro-peptide of collagen type III (PIIINP), and tissue inhibitor of matrix metalloprotease-1 (TIMP-1) (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest
Fibrotest combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT with adjustment for age and gender. Fibrotest is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e\^-z). Calculated score range from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for "Fibrotest" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Fibrotest calculated in 81 participants is -0.06 with a standard deviation of 0.08.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest
SteatoTest combines α2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, and ALT, adjusted for patient's age, sex, weight, and height. Patented formula. Calculated score range from 0 (no steatosis) to 1 (severe steatosis) In below table for "Steatotest" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Steatotest calculated in 81 participants is -0.09 with a standard deviation of 0.11.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score
Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. Score is calculated using the following formula: -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis. In below table for "Angulo index" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Angulo index calculated in 82 participants is 0.06 with a standard deviation of 0.53.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF)
Enhanced Liver Fibrosis (ELF) combines measurements of tissue inhibitor of metalloprotein-ases-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) . The ELF score is calculated as : 2.278 + 0.851 ln (HA) + 0.751 ln (PIIINP) + 0.394 ln (TIMP-1). ELF score range from An ELF score of less than 7.7 indicates no fibrosis. An ELF score greater than or equal to 9.8 indicates severe fibrosis. An ELF score of 11.3 or greater indicates cirrhosis. A decrease in ELF score represents a positive outcome In below table for "Enhanced Liver Fibrosis" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Enhanced Liver Fibrosis calculated in 81 analysed participants is -0.01 with a standard deviation of 0.54.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI)
The Fatty Liver Index (FLI) combines triglycerides, BMI, GGT and Waist circumference. FLI is calculated as : (e0.953×loge\[triglycerides\]+0.139× Body Mass Index\[BMI\]+0.718×loge Gamma- Glutamyl Transferase \[GGT\]+0.053×waistcircumference-15.745)/ (1 +e0.953×loge\[triglycerides\]+0.139×BMI+0.718×loge \[GGT\]+0.053×waistcircumference-15.745) × 100. Calculated index range from 0 to 100. FLI score below 30 indicate absence of Fatty Liver and FLI Score of 60 and above indicates presence of Fatty Liver. In below table for "Fatty Liver Index" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Fatty Liver Index calculated in 82 analysed participants is -7.94 with a standard deviation of 11.74.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer
Fibrometer combines Platelets, AST, ALT, ferritin, glucose (fasting plasma), Weight and gender. Patented formula. Score ranges from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for "Fibrometer" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Fibrometer calculated in 81 analysed participants is 0.04 with a standard deviation of 0.23.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in total bilirubin and conjugated bilirubin (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in prothrombin ratio (non-invasive marker of fibrosis and steatosis). The Prothrombin ratio is the ratio of a participants measured prothrombin time (in seconds) to the normal laboratory reference prothrombin time. Participants with missing data for Prothrombin ratio at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in international normalized ratio (INR; non-invasive marker of fibrosis and steatosis). Participants with missing data for International Normalized Ratio (INR) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in lipid parameters (used to assess cardiovascular risk)
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Outcomes Related to Biochemistry
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in secondary outcomes related to biochemistry
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Leptin
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in leptin (to assess insulin resistance).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Insulin
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in insulin (to assess insulin resistance). Participants with missing data for Insulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: C Peptide
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in C peptide (to assess insulin resistance). Participants with missing data for C Peptide at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in homeostatic model assessment-insulin resistance (HOMA-IR; to assess insulin resistance). The HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/l) / 22.5 A decrease in HOMA-IR indicates a positive outcome. HOMA-IR values of greater than 1.9 indicates early insulin resistance and levels above 2.9 indicate significant insulin resistance. Participants with missing data for HOMA-IR at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in free fatty acids (FFA; to assess insulin resistance). Participants with missing data for Free Fatty Acids (FFA) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in plasma glucose (to assess insulin resistance). Participants with missing data for Plasma Glucose at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in glycosylated haemoglobin A1c (HbA1c; to assess insulin resistance). Participants with missing data for Haemoglobin A1c (HbA1c) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in Fructosamine (to assess insulin resistance).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in fibrinogen and haptoglobin (inflammatory markers).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in tumour necrosis factor alpha and interleukine 6 (inflammatory markers).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in plasminogen activator inhibitor 1 (PAI-1; inflammatory marker). Participants with missing data for Plasminogen Activator Inhibitor 1 (PAI-1) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in C-Reactive Protein (CRP; inflammatory marker).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine (safety markers; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine clearance (safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in uric acid (safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in blood urea nitrogen (BUN; safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in cystatin C (safety marker; renal function parameter). Participants with missing data for Cystatin C at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in beta2-microglobulin (safety marker; renal function parameter). Participants with missing data for Beta2-microglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in N-terminal prohormone of brain natriuretic peptide (NT-proBNP; safety marker; cardiac function parameter). Participants with missing data for NT-proBNP at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in troponin T (safety marker; cardiac function parameter). Participants with missing data for Troponin T at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Changes From Baseline to Week 52 in Body Weight
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in body weight.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Recruitment for the GFT505-212-7 study began in September 2012. This was a phase IIb, double-blind, randomized, placebo-controlled study conducted in three parallel groups: placebo, GFT505 80mg and GFT505 120mg (after DSMB review of 6 month safety data of the 80mg dose on at least 50% of participants) once daily for 52 weeks.
| Milestone | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Started | 93 | 90 | 92 |
| Randomized | 93 | 90 | 92 |
| Randomised and received treatment (full analysis set and safety set) | 93 | 89 | 92 |
| Efficacy evaluable set | 82 | 78 | 77 |
| Completed | 84 | 79 | 78 |
| Not completed | 9 | 11 | 14 |
| Withdrew: Adverse event | 6 | 7 | 4 |
| Withdrew: Withdrawal by subject | 1 | 3 | 7 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Non-compliance | 1 | 0 | 1 |
| Withdrew: Randomized and not treated | 0 | 1 | 0 |
| Milestone | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Started | 84 | 79 | 78 |
| Completed | 83 | 76 | 77 |
| Not completed | 1 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
Percentage of responders from baseline to Week 52 defined by the disappearance of steatohepatitis (ie, participants no longer meeting the criteria for steatohepatitis) without worsening of fibrosis. Worsening of fibrosis was evaluated using Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis staging system and defined as: * Progression to stage 3 or 4 for participants at stage 0, 1 or 2 on diagnostic liver biopsy * Progression to stage 4 for participants at stage 3 on diagnostic liver biopsy
| Participants | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Efficacy evaluable set — Responders | 21 | 19 | 16 |
| Efficacy evaluable set — Non-responders | 61 | 59 | 61 |
| Full analysis set — Responders | 21 | 19 | 16 |
| Full analysis set — Non-responders | 72 | 70 | 76 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg the change from baseline to Week 52, in Non-alcoholic Fatty Liver Disease Activity Score (NAS score). NAS score is a composite score equal to the sum of the steatosis grade (0 to 3), lobular inflammation grade (0 to 3) and hepatocellular ballooning grade (0 to 2). The overall scale of the NAS is 0 to 8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome.
| NAS score | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | -0.65 ± 1.33 | -0.64 ± 1.68 | -0.45 ± 1.34 |
To evaluate the number of participants with at least a 2 point decrease from baseline in Non-alcoholic Fatty Liver Disease Activity Score (NAS) after 52 weeks of daily administration of GFT505 80mg or 120mg. The NAS refers to the severity of ongoing liver injury as assessed by a liver biopsy and is used to assess the activity of the disease. It is based on the NASH CRN methodology for scoring the severity of steatosis (score of 0 to 3), inflammation (score of 0 to 3), and hepatocellular ballooning (score of 0 to 2), with a maximum score of 8. A total NAS score of five or greater correlates with the diagnosis of steatohepatitis. In table below for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 2 participants (out of 10 participants analysed with a baseline NAS at 3) had at Least 2 points decrease on their NAS after 52 weeks of daily administration of GFT505 80mg. It corresponds to 20% (2 out of 10).
| Participants | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 2 | 2 | 5 |
| Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 11 | 12 | 9 |
| Severe (Non-alcoholic Fatty Liver Disease Activity Score 6-8) | 8 | 12 | 7 |
| Total | 21 | 26 | 21 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in steatosis score of at least 1 point between baseline and Week 52. Steatosis is assessed by a liver biopsy and evaluated on a scale of 0 to 3 with higher scores indicating more severe steatosis. A score of 0 indicating a lower severity with low parenchymal involvement (\<5%), while a score of 3 is indicative of higher involvment/severity (\> 66%). In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease Steatosis Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
| Participants | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 1 | 1 | 0 |
| Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 13 | 10 | 12 |
| Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 3 | 10 | 3 |
| Total | 17 | 21 | 15 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in lobular inflammation score of at least 1 point between baseline and Week 52. Lobular inflammation is assessed by a liver biopsy and evaluated on a scale of 0 to 3. A score of 0 indicating the absence of inflammation loci, while a score of 3 is indicative of a higher degree of inflammation with more than 4 inflammation loci 200 x field. In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Lobular Inflammation Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
| Participants | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 1 | 2 | 7 |
| Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 10 | 11 | 8 |
| Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 14 | 16 | 12 |
| Total | 25 | 29 | 27 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in ballooning score of at least 1 point between baseline and Week 52. Ballooning is assessed by a liver biopsy and evaluated on a scale of 0 to 2 with higher scores indicating more severe ballooning (0: No ballooned cells, 1: Few \[rare but definite\] ballooned hepatocytes; 2: Many ballooned cells/prominent ballooning). In below table and for helping how results are reported, as an example for raw "Mild (Nonalcoholic Fatty Liver Disease Activity Score 3)" and the column "GFT505 80mg" the result should be read as : 4 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Ballooning Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
| Participants | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 4 | 3 | 6 |
| Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 17 | 15 | 13 |
| Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 10 | 12 | 5 |
| Total | 31 | 30 | 24 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in stages of fibrosis (based on Non-Alcoholic Steatohepatitis Clinical Research Network \[NASH CRN\] scoring). Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
| Change in fibrosis score | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in the Stages of Fibrosis | -0.23 ± 0.84 | -0.06 ± 0.96 | -0.23 ± 0.90 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in liver enzymes.
| U/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Gamma-glutamyl transferase | -24.32 ± 36.39 | -20.59 ± 40.45 | 6.22 ± 50.64 |
| Aspartate transaminase | 1.88 ± 27.76 | -1.37 ± 24.74 | -1.32 ± 16.63 |
| Alanine aminotransferase | -7.02 ± 36.21 | -12.54 ± 44.72 | -3.26 ± 24.67 |
| Alkaline phosphatases | -18.82 ± 13.23 | -20.44 ± 16.47 | 3.44 ± 13.16 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in aspartate transaminase/alanine aminotransferase ratio
| ratio | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio | 0.15 ± 0.21 | 0.20 ± 0.25 | 0.01 ± 0.25 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK 18-M65 (non-invasive markers of fibrosis and steatosis).
| U/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65 | 104.4 ± 804.96 | -185.01 ± 658.14 | -45.53 ± 437.21 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK18 M30 (non-invasive markers of fibrosis and steatosis). Participants with missing data for CK18 M30 at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| pmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30 | -28.08 ± 574.50 | -66.40 ± 432.02 | -51.39 ± 349.64 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in adiponectin (non-invasive markers of fibrosis and steatosis).
| μg/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin | 4.98 ± 20.25 | 1.90 ± 8.34 | 2.54 ± 9.48 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in ferritin (non-invasive markers of fibrosis and steatosis). Participants with missing data for Ferritin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| μg/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin | -23.52 ± 145.61 | -19.68 ± 81.91 | -19.26 ± 122.57 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in FG19 and FG21 (non-invasive markers of fibrosis and steatosis).
| pg/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| FG19 | -27.25 ± 94.19 | -26.03 ± 91.59 | 11.64 ± 87.10 |
| FG21 | 258.74 ± 1138.36 | 319.68 ± 433.63 | 73.05 ± 360.41 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in alpha2 macroglobulin (a non-invasive marker of fibrosis and steatosis). Participants with missing data for Alpha2 Macroglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| g/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin | -0.14 ± 0.29 | -0.26 ± 0.36 | 0.01 ± 0.28 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in hyaluronic acid, N-terminal pro-peptide of collagen type III (PIIINP), and tissue inhibitor of matrix metalloprotease-1 (TIMP-1) (non-invasive markers of fibrosis and steatosis).
| ng/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Hyaluronic acid | 26.12 ± 230.97 | 12.14 ± 48.04 | 12.49 ± 48.68 |
| PIIINP | -0.50 ± 3.43 | -0.57 ± 3.75 | 0.29 ± 4.87 |
| TIMP-1 | 15.21 ± 35.38 | -6.32 ± 39.75 | 9.08 ± 49.54 |
Fibrotest combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT with adjustment for age and gender. Fibrotest is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e\^-z). Calculated score range from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for "Fibrotest" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Fibrotest calculated in 81 participants is -0.06 with a standard deviation of 0.08.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest | -0.06 ± 0.08 | -0.07 ± 0.09 | -0.01 ± 0.10 |
SteatoTest combines α2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, and ALT, adjusted for patient's age, sex, weight, and height. Patented formula. Calculated score range from 0 (no steatosis) to 1 (severe steatosis) In below table for "Steatotest" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Steatotest calculated in 81 participants is -0.09 with a standard deviation of 0.11.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest | -0.09 ± 0.11 | -0.08 ± 0.15 | 0.03 ± 0.11 |
Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. Score is calculated using the following formula: -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis. In below table for "Angulo index" and for column "GFT505 80mg" the result should be read as: the mean of change from baseline to week 52 of Angulo index calculated in 82 participants is 0.06 with a standard deviation of 0.53.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score | 0.06 ± 0.53 | -0.26 ± 0.57 | -0.01 ± 0.51 |
Enhanced Liver Fibrosis (ELF) combines measurements of tissue inhibitor of metalloprotein-ases-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) . The ELF score is calculated as : 2.278 + 0.851 ln (HA) + 0.751 ln (PIIINP) + 0.394 ln (TIMP-1). ELF score range from An ELF score of less than 7.7 indicates no fibrosis. An ELF score greater than or equal to 9.8 indicates severe fibrosis. An ELF score of 11.3 or greater indicates cirrhosis. A decrease in ELF score represents a positive outcome In below table for "Enhanced Liver Fibrosis" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Enhanced Liver Fibrosis calculated in 81 analysed participants is -0.01 with a standard deviation of 0.54.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF) | -0.01 ± 0.54 | -0.01 ± 0.64 | 0.08 ± 0.70 |
The Fatty Liver Index (FLI) combines triglycerides, BMI, GGT and Waist circumference. FLI is calculated as : (e0.953×loge\[triglycerides\]+0.139× Body Mass Index\[BMI\]+0.718×loge Gamma- Glutamyl Transferase \[GGT\]+0.053×waistcircumference-15.745)/ (1 +e0.953×loge\[triglycerides\]+0.139×BMI+0.718×loge \[GGT\]+0.053×waistcircumference-15.745) × 100. Calculated index range from 0 to 100. FLI score below 30 indicate absence of Fatty Liver and FLI Score of 60 and above indicates presence of Fatty Liver. In below table for "Fatty Liver Index" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Fatty Liver Index calculated in 82 analysed participants is -7.94 with a standard deviation of 11.74.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI) | -7.94 ± 11.74 | -7.81 ± 14.29 | 1.34 ± 11.65 |
Fibrometer combines Platelets, AST, ALT, ferritin, glucose (fasting plasma), Weight and gender. Patented formula. Score ranges from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for "Fibrometer" and for column "GFT505 80mg" the result should be read as : the mean of change from baseline to week 52 of Fibrometer calculated in 81 analysed participants is 0.04 with a standard deviation of 0.23.
| score on a scale | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer | 0.04 ± 0.23 | 0 ± 0.20 | 0.02 ± 0.22 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in total bilirubin and conjugated bilirubin (non-invasive markers of fibrosis and steatosis).
| umol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Total bilirubin | -1.53 ± 3.66 | -1.38 ± 4.85 | -1.46 ± 3.77 |
| Conjugated bilirubin | -0.35 ± 1.26 | -0.15 ± 1.24 | -0.26 ± 1.05 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in prothrombin ratio (non-invasive marker of fibrosis and steatosis). The Prothrombin ratio is the ratio of a participants measured prothrombin time (in seconds) to the normal laboratory reference prothrombin time. Participants with missing data for Prothrombin ratio at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| ratio | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio | -3.85 ± 11.57 | 1.29 ± 10.03 | 0.51 ± 14.28 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in international normalized ratio (INR; non-invasive marker of fibrosis and steatosis). Participants with missing data for International Normalized Ratio (INR) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| ratio | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR) | 0.03 ± 0.09 | -0.01 ± 0.08 | 0.03 ± 0.39 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in lipid parameters (used to assess cardiovascular risk)
| mmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Triglycerides | -0.33 ± 0.76 | -0.48 ± 0.90 | 0.16 ± 1.12 |
| Cholesterol | -0.42 ± 0.78 | -0.42 ± 0.72 | 0.02 ± 0.66 |
| Non-high Density Lipoproteins Cholesterol | -0.45 ± 0.79 | -0.47 ± 0.71 | 0.07 ± 0.67 |
| High Density Lipoproteins Cholesterol | 0.02 ± 0.17 | 0.06 ± 0.23 | -0.06 ± 0.21 |
| Very Low Density Lipoproteins Cholesterol | -0.17 ± 0.28 | -0.17 ± 0.32 | 0.05 ± 0.23 |
| Low Density Lipoproteins Cholesterol | -0.27 ± 0.70 | -0.25 ± 0.61 | -0.01 ± 0.51 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in secondary outcomes related to biochemistry
| mg/dL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Apo A1 | 1.63 ± 15.59 | 2.85 ± 20.42 | -3.90 ± 16.53 |
| Apo B | -12.80 ± 20.87 | -8.42 ± 16.03 | 0.94 ± 14.29 |
| Apo AII | -0.15 ± 6.63 | 4.25 ± 4.36 | -3.36 ± 4.82 |
| Apo CIII | -1.79 ± 3.91 | -0.69 ± 3.42 | 0.77 ± 4.30 |
| Apo CIII/B | -1.44 ± 2.98 | -0.65 ± 2.98 | 0.53 ± 3.05 |
| Apo CIII/nonB | -0.35 ± 1.79 | -0.04 ± 0.76 | 0.24 ± 2.53 |
| Small dense Low Density Lipoproteins | -2.09 ± 11.02 | -2.62 ± 6.08 | 0.60 ± 7.52 |
| Lp(a) | -0.57 ± 12.24 | -0.91 ± 13.75 | 0.80 ± 4.46 |
| Apo E | -1.72 ± 2.75 | -1.38 ± 2.99 | -0.29 ± 3.67 |
| Apo E/B | -1.43 ± 2.43 | -1.48 ± 2.64 | -0.21 ± 2.59 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in leptin (to assess insulin resistance).
| ng/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Leptin | -0.21 ± 9.55 | 3.51 ± 10.67 | 3.01 ± 8.08 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in insulin (to assess insulin resistance). Participants with missing data for Insulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| pmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Insulin | -33.88 ± 189.64 | -26.12 ± 111.76 | 8.92 ± 112.26 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in C peptide (to assess insulin resistance). Participants with missing data for C Peptide at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| nmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: C Peptide | -0.17 ± 0.55 | -0.03 ± 0.48 | 0.12 ± 0.58 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in homeostatic model assessment-insulin resistance (HOMA-IR; to assess insulin resistance). The HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/l) / 22.5 A decrease in HOMA-IR indicates a positive outcome. HOMA-IR values of greater than 1.9 indicates early insulin resistance and levels above 2.9 indicate significant insulin resistance. Participants with missing data for HOMA-IR at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| HOMA-IR score | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR) | -1.10 ± 10.76 | -1 ± 6.86 | 1.01 ± 4.96 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in free fatty acids (FFA; to assess insulin resistance). Participants with missing data for Free Fatty Acids (FFA) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| mmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA) | -0.04 ± 0.25 | -0.04 ± 0.24 | 0.05 ± 0.26 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in plasma glucose (to assess insulin resistance). Participants with missing data for Plasma Glucose at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| mmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose | 0.17 ± 1.23 | 0.22 ± 1.70 | 0.67 ± 1.95 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in glycosylated haemoglobin A1c (HbA1c; to assess insulin resistance). Participants with missing data for Haemoglobin A1c (HbA1c) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| percentage of HbA1c | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c) | 0.22 ± 0.56 | 0.03 ± 0.70 | 0.25 ± 0.69 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in Fructosamine (to assess insulin resistance).
| umol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine | 16.27 ± 27.53 | -8.24 ± 28.21 | 11.29 ± 28.62 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in fibrinogen and haptoglobin (inflammatory markers).
| g/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Fibrinogen | -0.37 ± 0.70 | -0.37 ± 0.79 | -0.05 ± 0.66 |
| Haptoglobin | -0.19 ± 0.32 | -0.20 ± 0.40 | 0.09 ± 0.35 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in tumour necrosis factor alpha and interleukine 6 (inflammatory markers).
| pg/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Tumour Necrosis Factor alpha | 1.37 ± 6.14 | -2.45 ± 38.58 | 0.19 ± 10.46 |
| Interleukine 6 | 0.37 ± 4.20 | -1.14 ± 10.33 | -0.06 ± 1.37 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in plasminogen activator inhibitor 1 (PAI-1; inflammatory marker). Participants with missing data for Plasminogen Activator Inhibitor 1 (PAI-1) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow
| ng/mL | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1) | -0.51 ± 3.51 | 0.21 ± 4.28 | -0.14 ± 4.74 |
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in C-Reactive Protein (CRP; inflammatory marker).
| Log (mg/L) | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP) | -0.04 ± 0.72 | -0.05 ± 0.81 | 0.20 ± 0.74 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine (safety markers; renal function parameter).
| μmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter) | 2.03 ± 7.89 | 5.61 ± 8.18 | 1.27 ± 7.85 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine clearance (safety marker; renal function parameter).
| mL/min | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter) | -0.06 ± 0.94 | -0.56 ± 2.22 | -0.09 ± 0.62 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in uric acid (safety marker; renal function parameter).
| mmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter) | 0 ± 0.06 | 0.01 ± 0.05 | -0.01 ± 0.06 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in blood urea nitrogen (BUN; safety marker; renal function parameter).
| mmol urea/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter) | 0.61 ± 1.28 | 0.67 ± 1.22 | -0.17 ± 1.14 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in cystatin C (safety marker; renal function parameter). Participants with missing data for Cystatin C at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| mg/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter) | 0.05 ± 0.10 | 0.04 ± 0.22 | 0.04 ± 0.13 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in beta2-microglobulin (safety marker; renal function parameter). Participants with missing data for Beta2-microglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| μg/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter) | -22.26 ± 326.42 | 0.11 ± 466.43 | -83.48 ± 279.31 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in N-terminal prohormone of brain natriuretic peptide (NT-proBNP; safety marker; cardiac function parameter). Participants with missing data for NT-proBNP at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| pmol/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter) | 1.54 ± 4.16 | 0.38 ± 4.81 | -1.24 ± 5.35 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in troponin T (safety marker; cardiac function parameter). Participants with missing data for Troponin T at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the "Efficacy Evaluable Set" of the Participant Flow.
| μg/L | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in body weight.
| kg | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Changes From Baseline to Week 52 in Body Weight | 0.11 ± 3.61 | -0.69 ± 4.09 | -0.04 ± 3.40 |
Collected over Adverse event information was collected at every study visit from screening up to the termination of the study corresponding to 64 weeks.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GFT505 80mg | 0/93 (0%) | 12/93 (12.9%) | 85/93 (91.4%) |
| GFT505 120mg | 0/89 (0%) | 14/89 (15.7%) | 86/89 (96.6%) |
| Placebo | 0/92 (0%) | 9/92 (9.8%) | 85/92 (92.4%) |
| Event | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| Pancreatitis AcuteGastrointestinal disorders | 0/93 | 2/89 | 0/92 |
| VertigoEar and labyrinth disorders | 0/93 | 1/89 | 0/92 |
| Non-cardiac chest painGeneral disorders | 0/93 | 1/89 | 0/92 |
| SepsisInfections and infestations | 0/93 | 1/89 | 0/92 |
| Ankle fractureInjury, poisoning and procedural complications | 0/93 | 1/89 | 0/92 |
| OverdoseInjury, poisoning and procedural complications | 0/93 | 1/89 | 0/92 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/93 | 1/89 | 0/92 |
| Diabetes ketoacidosisMetabolism and nutrition disorders | 0/93 | 1/89 | 0/92 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/93 | 1/89 | 0/92 |
| Parathyroid tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/93 | 1/89 | 0/92 |
| Event | GFT505 80mg | GFT505 120mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 18/93 | 17/89 | 14/92 |
| HeadacheNervous system disorders | 16/93 | 12/89 | 15/92 |
| FatigueGeneral disorders | 13/93 | 12/89 | 14/92 |
| DiarrhoeaGastrointestinal disorders | 14/93 | 9/89 | 6/92 |
| Abdominal pain upperGastrointestinal disorders | 12/93 | 9/89 | 13/92 |
| LeukocyturiaRenal and urinary disorders | 10/93 | 8/89 | 12/92 |
| Abdominal painGastrointestinal disorders | 9/93 | 11/89 | 11/92 |
| Procedural painInjury, poisoning and procedural complications | 6/93 | 11/89 | 10/92 |
| BronchitisInfections and infestations | 10/93 | 6/89 | 8/92 |
| InfluenzaInfections and infestations | 10/93 | 3/89 | 5/92 |
| Age, Continuous(years) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 53.26 ± 11.02 | 52.88 ± 11.63 | 52.88 ± 11.99 | 53.01 ± 11.51 |
| Sex: Female, Male(Participants) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Female | 44 | 42 | 37 | 123 |
| Male | 49 | 47 | 55 | 151 |
| Race/Ethnicity, Customized(Participants) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Race — Caucasian | 88 | 71 | 85 | 244 |
| Race — Black | 2 | 5 | 3 | 10 |
| Race — Asian | 0 | 6 | 1 | 7 |
| Race — Other | 3 | 7 | 3 | 13 |
| Body Mass Index (BMI)(kg/m^2) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 31.80 ± 5.20 | 31.04 ± 4.39 | 30.91 ± 4.15 | 31.25 ± 4.61 |
| Type 2 diabetes(participants) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Type 2 diabetes (Yes) | 37 | 37 | 33 | 107 |
| Type 2 diabetes (No) | 56 | 52 | 59 | 167 |
| Height(cm) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 167.77 ± 9.30 | 170.21 ± 10.69 | 169.21 ± 10.23 | 169.05 ± 10.09 |
| Weight(kg) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 89.62 ± 17.76 | 90.15 ± 15.57 | 88.72 ± 15.79 | 89.49 ± 16.36 |
| Waist Circumference(cm) | GFT505 80mg | GFT505 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 106.41 ± 13.09 | 106.26 ± 10.28 | 104.68 ± 10.52 | 105.78 ± 11.37 |
The record gives a start of Sep 2012, a primary completion of Feb 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2022, 7 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor
Non-alcoholic Fatty Liver Disease →